8-K Announcements
6Material company update
Apr 28, 2026·SEC
Material company update
Nov 4, 2025·SEC
Material company update
Oct 28, 2025·SEC
Nautilus Biotechnology, Inc.(NAUT)Earnings, Financials & Key Ratios
NAUT•NASDAQ
$1.69
Price updated Jul 7, 2026
AboutNautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.Show more
- Revenue$0
- EBITDA-$60M+19.6%
- Net Income-$59M+16.6%
- EPS (Diluted)-0.47+16.1%
- ROE-32.27%-8.1%
NAUT Price & Volume
Nautilus Biotechnology, Inc. (NAUT) stock price & volume — 10-year historical chart
Loading chart...
Pre-Revenue Proteomics Platform Faces Liquidity Constraints
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Imminent liquidity and commercialization
Key Thesis Takeaways
- Nautilus Biotechnology remains a high-risk, pre-commercial entity with no revenue generation over the last ten quarters, necessitating a critical evaluation of its ability to reach market viability.
- The company's heavy reliance on R&D, which averaged $10.8 million per quarter, continues to erode its asset base, which has contracted from $305.6 million in 2023Q4 to $177.8 million in 2026Q1.
- Investors should monitor the company's ability to secure additional capital, as the current cash position of $12.4 million appears insufficient to sustain its ongoing operational burn rate.
Verdict Logic
the company's cash position of $12.4 million is critically low relative to its historical quarterly free cash flow burn of approximately $14 million, indicating a high probability of near-term dilution or insolvency risk.
NAUT Growth Metrics
Nautilus Biotechnology, Inc. (NAUT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM16.86%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM14.81%
Return on Capital
10 Years-30.67%
5 Years-25%
3 Years-28.81%
Last Year-31.96%
NAUT Recent Earnings
Nautilus Biotechnology, Inc. (NAUT) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)
Q2 2026Latest
Apr 28, 2026Metric
Actual
Est
EPS
$0.12+17.2%
$0.14
Rev
—
$250,000
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.11+21.4%
$0.14
Rev
—
$1M
Q4 2025
Oct 27, 2025Metric
Actual
Est
EPS
$0.11+26.7%
$0.15
Rev
—
—
Q3 2025
Jul 31, 2025Metric
Actual
Est
EPS
$0.12+22.6%
$0.15
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 28, 2026 | $0.12vs $0.14+17.2% | —vs $250,000 |
| Q1 2026 | Feb 26, 2026 | $0.11vs $0.14+21.4% | —vs $1M |
| Q4 2025 | Oct 27, 2025 | $0.11vs $0.15+26.7% | — |
| Q3 2025 | Jul 31, 2025 | $0.12vs $0.15+22.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Nautilus Biotechnology, Inc. (NAUT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.69 | $214.76M | -3.60 | — | — | -32.27% | — | |
| $28.31 | $1.46B | -70.78 | 13.79% | -1.98% | -2.61% | — | |
| $2.22 | $122.06M | -1.73 | 15.57% | -468.74% | -26.58% | — | |
| $21.06 | $7.73B | -18.97 | 178.54% | -2957.23% | -44.05% | — | |
| $191.76 | $29.13B | 35.19 | -0.78% | 19.43% | 32.84% | — | |
| $1.56 | $484.54M | -0.86 | 3.89% | -80.34% | -488.45% | — |
Compare NAUT vs Peers
Nautilus Biotechnology, Inc. (NAUT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NAUT SEC Filings & Documents
Nautilus Biotechnology, Inc. (NAUT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NAUT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NAUT Frequently Asked Questions
Nautilus Biotechnology, Inc. (NAUT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is NAUT profitable?
Nautilus Biotechnology, Inc. (NAUT) reported a net loss of $57.1M for fiscal year 2025.
Dividend & Returns
What is NAUT's return on equity?
Nautilus Biotechnology, Inc. (NAUT) has a return on equity (ROE) of -32.3%. Negative ROE indicates the company is unprofitable.
What is Nautilus Biotechnology, Inc.'s free cash flow?
Nautilus Biotechnology, Inc. (NAUT) had negative free cash flow of $51.4M in fiscal year 2025, likely due to heavy capital investments.